leadf
logo-loader
viewBioLargo, Inc.

BioLargo says subsidiary's Clyraguard protective spray inactivates SARS-CoV-2 virus in lab tests

Clyraguard is a clear personal spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment

Clyraguard bottle
Clyraguard is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining

BioLargo Inc (OTCQB:BLGO) announced Thursday that Clyraguard, a spray developed by subsidiary Clyra Medical Technologies, was shown to cause complete inactivation of the SARS-CoV-2 virus in lab testing.

Clyraguard is a personal protective spray designed to help frontline healthcare workers prevent cross-contamination of their personal protective equipment from SARS-CoV-2, the virus that causes COVID-19.

The product is colorless and odorless and has been found to be non-toxic, non-irritating, non-sensitizing and non-staining. Testing was conducted under the supervision of Dr Slobodan Paessler at the Galveston National Laboratory at the University of Texas Medical Branch.

READ: BioLargo Inc clocked record revenue in 2019 driven by new channel partnerships, commercial milestones

“We are very proud of the Clyra team for creating this powerful tool to help fight the spread of SARS-CoV-2,” BioLargo CEO Dennis Calvert said. “Clyraguard will help protect people as we continue to fight the spread of the pandemic and will help people get back to living their lives.”

Along with and in addition to its subsidiary Clyra Medical, BioLargo has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination and advanced wound care. 

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: BioLargo, Inc.

Price: 0.1548 USD

OTCMKTS:BLGO
Market: OTCQB
Market Cap: $33.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

BioLargo reveals 60% rise in 3Q revenue amidst roll-out of PPE disinfectant...

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tell Proactive the group posted third-quarter results on Thursday that saw its revenue jump 60% year-over-year on the back of contributions from all four of its divisions including its subsidiary Clyra Medical Technologies. Clyra Medical Technologies...

1 week, 4 days ago

2 min read